Dosage strategies for delaying resistance emergence in heterogeneous tumors

Drug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resist...

Full description

Bibliographic Details
Main Authors: Vahideh Vakil, Wade Trappe
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:FEBS Open Bio
Subjects:
Online Access:https://doi.org/10.1002/2211-5463.13129
id doaj-ac786fddba9444c9b4215c88917dbb5c
record_format Article
spelling doaj-ac786fddba9444c9b4215c88917dbb5c2021-05-03T11:42:20ZengWileyFEBS Open Bio2211-54632021-05-011151322133110.1002/2211-5463.13129Dosage strategies for delaying resistance emergence in heterogeneous tumorsVahideh Vakil0Wade Trappe1Wireless Information Network Laboratory (WINLAB) Rutgers, The State University of New Jersey New Brunswick NJ USAWireless Information Network Laboratory (WINLAB) Rutgers, The State University of New Jersey New Brunswick NJ USADrug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resistant subpopulations in the tumor environment. In this paper, we present a mathematical framework involving clonal evolution modeling of drug‐sensitive and drug‐resistant clones. Using our framework, we examine delaying the rise of resistance in heterogeneous tumors during control phase of therapy in a containment treatment approach. We apply pharmacokinetic/pharmacodynamic (PKPD) modeling and show that dosage strategies can be designed to control the resistant subpopulation. Our results show that the drug dosage and schedule determine the relative dynamics of sensitive and resistant clones. We present an optimal control problem that finds the dosing strategy that maximizes the delay in resistance emergence for a given period of containment treatment.https://doi.org/10.1002/2211-5463.13129clonal evolutioncontainmentdosage strategydrug resistanceoptimal control
collection DOAJ
language English
format Article
sources DOAJ
author Vahideh Vakil
Wade Trappe
spellingShingle Vahideh Vakil
Wade Trappe
Dosage strategies for delaying resistance emergence in heterogeneous tumors
FEBS Open Bio
clonal evolution
containment
dosage strategy
drug resistance
optimal control
author_facet Vahideh Vakil
Wade Trappe
author_sort Vahideh Vakil
title Dosage strategies for delaying resistance emergence in heterogeneous tumors
title_short Dosage strategies for delaying resistance emergence in heterogeneous tumors
title_full Dosage strategies for delaying resistance emergence in heterogeneous tumors
title_fullStr Dosage strategies for delaying resistance emergence in heterogeneous tumors
title_full_unstemmed Dosage strategies for delaying resistance emergence in heterogeneous tumors
title_sort dosage strategies for delaying resistance emergence in heterogeneous tumors
publisher Wiley
series FEBS Open Bio
issn 2211-5463
publishDate 2021-05-01
description Drug resistance in cancer treatments is a frequent problem that, when it arises, leads to failure in therapeutic efforts. Tumor heterogeneity is the primary reason for resistance emergence and a precise treatment design that takes heterogeneity into account is required to postpone the rise of resistant subpopulations in the tumor environment. In this paper, we present a mathematical framework involving clonal evolution modeling of drug‐sensitive and drug‐resistant clones. Using our framework, we examine delaying the rise of resistance in heterogeneous tumors during control phase of therapy in a containment treatment approach. We apply pharmacokinetic/pharmacodynamic (PKPD) modeling and show that dosage strategies can be designed to control the resistant subpopulation. Our results show that the drug dosage and schedule determine the relative dynamics of sensitive and resistant clones. We present an optimal control problem that finds the dosing strategy that maximizes the delay in resistance emergence for a given period of containment treatment.
topic clonal evolution
containment
dosage strategy
drug resistance
optimal control
url https://doi.org/10.1002/2211-5463.13129
work_keys_str_mv AT vahidehvakil dosagestrategiesfordelayingresistanceemergenceinheterogeneoustumors
AT wadetrappe dosagestrategiesfordelayingresistanceemergenceinheterogeneoustumors
_version_ 1721482456050171904